Quest Diagnostics has agreed to acquire Celera in a merger deal valued at US$344 M, net of US$327 M in acquired cash and short-term investments. The US$8 per share offered by Quest represents a 28% premium over Celera’s closing share price prior to the announcement of the transaction. With the acquisition, Quest will gain Celera’s portfolio of genetic testing products, including its Berkeley HeartLab cardiovascular testing business, along with its biomarker pipeline and proteomics platform.